IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

被引：2
|
作者：
French, Pim [1 ]
Erdem-Eraslan, L. [1 ]
Kros, J. M. [1 ]
Oosterkamp, H. M. [1 ]
Walenkamp, A. M. E. [1 ]
Beerepoot, L. [1 ]
Hanse, M. [1 ]
Buter, J. [1 ]
Honkoop, A. [1 ]
van der Holt, B. [1 ]
Vernhout, R. M. [1 ]
Smitt, P. A. E. Sillevis [1 ]
Taal, W. [1 ]
van den Bent, M. J. [1 ]
机构：
[1] Erasmus MC Canc Ctr, Rotterdam, Netherlands
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou206.29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB
    Eraslan, Lale Erdem
    van den Bent, Martin
    Kros, Johan
    Oosterkamp, Hendrika
    Walenkamp, Annemiek
    Beerepoot, Laurens
    Hanse, Monique
    Buter, J.
    Honkoop, Aafke
    van der Holt, Bronno
    Vernhout, R. M.
    Smitt, Peter Sillevis
    Taal, Walter
    French, Pim
    NEURO-ONCOLOGY, 2014, 16
  • [2] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [3] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
    Raval, S.
    Hwang, S.
    Dorsett, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
    Erdem-Eraslan, Lale
    van den Bent, Martin J.
    Hoogstrate, Youri
    Naz-Khan, Hina
    Stubbs, Andrew
    van der Spek, Peter
    Bottcher, Rene
    Gao, Ya
    de Wit, Maurice
    Taal, Walter
    Oosterkamp, Hendrika M.
    Walenkamp, Annemiek
    Beerepoot, Laurens V.
    Hanse, Monique C. J.
    Buter, Jan
    Honkoop, Aafke H.
    van der Holt, Bronno
    Vernhout, Rene M.
    Smitt, Peter A. E. Sillevis
    Kros, Johan M.
    French, Pim J.
    CANCER RESEARCH, 2016, 76 (03) : 525 - 534
  • [5] Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).
    Gleeson, Jack Patrick
    Alhusaini, Abdullah
    O'Halloran, Philip
    Harrold, Emily
    Keegan, Niamh M.
    Karadawi, Nabeeha Eltag
    Mammadov, Emin
    Kamel, Dalia
    Egan, Keith
    Molloy, Susan
    Hennessy, Bryan T.
    Breathnach, Oscar S.
    Grogan, William
    Morris, Patrick G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
    Andre, J.
    Spearman, K.
    Lu, S.
    Hwang, S.
    Dorsett, L.
    Raval, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
    Andre, Jalal
    Spearman, Kenneth
    Lu, Stanley
    Raval, Sumul
    NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
  • [8] BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?
    Smolenschi, Cristina
    Colomba, Emeline
    Rassy, Elie
    Lezghed, Naima
    Kettab, Mohamed
    Louvel, Guillaume
    Garcia, Gabriel
    Cheaib, Bianca
    Bockel, Sophie
    Pallud, Johan
    Dezamis, Edouard
    Copaciu, Razvan
    Knafo, Steven
    Ammari, Samy
    Dhermain, Frederic
    Domont, Julien
    Martanovschi, Larisa
    Mahmoud, Fekih
    Dumont, Sarah
    NEURO-ONCOLOGY, 2020, 22 : 133 - 133
  • [9] BENEFIT OF BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA. RESULTS OF 81 PATIENTS FROM A SINGLE INSTITUTION
    Absalyamova, O.
    Kobiakov, G.
    Agabekyan, G.
    Poddubsky, A.
    Belyashova, A.
    Lodygina, K.
    Absalyamov, A.
    Kobiakov, N.
    NEURO-ONCOLOGY, 2019, 21 : 69 - 69
  • [10] Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
    Maron, R.
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Quinn, J. A.
    Rich, J. N.
    Gururangan, S.
    Wagner, S. A.
    Salacz, M. E.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345